Allogene Therapeutics Files Prospectus For $500M Offering
-SEC Filing
Read original at benzingaStocks · News reference
Citizens Reiterates Market Outperform on Allogene Therapeutics, Maintains $6 Price Target
Citizens analyst Reni J. Benjamin reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Market Outperform and maintains $6 price target.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 17, 2026, 12:59 PM
- Checked
- Aug 17, 2026, 12:59 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — Allogene Therapeutics, Inc. (ALLO)
Filed: 2026-08-12 AccNo: 0001628280-26-056198 Size: 213 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarAllogene Therapeutics Q2 EPS $(0.13) Beats $(0.17) Estimate, Sales $4.640M Beat $2.222K Estimate
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.17) by 23.53 percent. This is a 43.48 percent increase over losses of $(0.23) per share
Read original at benzinga